ABVC BioPharma, Inc. (ABVC)
ABVC Stock Price Chart
Explore ABVC BioPharma, Inc. interactive price chart. Choose custom timeframes to analyze ABVC price movements and trends.
ABVC Company Profile
Discover essential business fundamentals and corporate details for ABVC BioPharma, Inc. (ABVC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Nov 2004
Employees
16.00
Website
https://www.abvcpharma.comCEO
Uttam Yashwant Patil
Description
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
ABVC Financial Timeline
Browse a chronological timeline of ABVC BioPharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Apr 2026
Upcoming earnings on 12 Nov 2025
Earnings released on 13 Aug 2025
EPS came in at -$0.13 .
Earnings released on 30 Apr 2025
EPS came in at -$0.06 .
Earnings released on 15 Apr 2025
EPS came in at $0.04 , while revenue for the quarter reached $1.97K .
Earnings released on 14 Nov 2024
EPS came in at -$0.02 , while revenue for the quarter reached $389.28K .
Earnings released on 14 Aug 2024
EPS came in at -$0.09 , while revenue for the quarter reached $117.14K .
Earnings released on 17 May 2024
EPS came in at -$0.40 , while revenue for the quarter reached $1.21K .
Earnings released on 13 Mar 2024
EPS came in at -$0.35 surpassing the estimated -$0.50 by +30.00%, while revenue for the quarter reached $2.17K .
Earnings released on 15 Nov 2023
EPS came in at -$0.82 falling short of the estimated -$0.40 by -105.00%, while revenue for the quarter reached $15.88K , missing expectations by -94.71%.
Earnings released on 14 Aug 2023
EPS came in at -$0.68 falling short of the estimated -$0.60 by -13.33%, while revenue for the quarter reached $6.11K , missing expectations by -97.96%.
Stock split effective on 25 Jul 2023
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 May 2023
EPS came in at -$0.60 falling short of the estimated -$0.50 by -20.00%, while revenue for the quarter reached $128.27K .
Earnings released on 31 Mar 2023
EPS came in at -$1.50 surpassing the estimated -$1.90 by +21.05%, while revenue for the quarter reached $588.99K , beating expectations by +5.79K%.
Earnings released on 14 Nov 2022
EPS came in at -$1.10 surpassing the estimated -$2.00 by +45.00%, while revenue for the quarter reached $42.27K , beating expectations by +61.48%.
Earnings released on 15 Aug 2022
EPS came in at -$0.60 surpassing the estimated -$2.00 by +70.00%, while revenue for the quarter reached $312.86K , beating expectations by +1.11K%.
Earnings released on 16 May 2022
EPS came in at -$2.00 , while revenue for the quarter reached $25.66K .
Earnings released on 31 Mar 2022
EPS came in at -$0.31 falling short of the estimated -$0.04 by -675.00%, while revenue for the quarter reached -$37.79K .
Earnings released on 15 Nov 2021
EPS came in at -$0.70 falling short of the estimated -$0.40 by -75.00%, while revenue for the quarter reached $99.00K , missing expectations by -31.46%.
Earnings released on 12 Aug 2021
EPS came in at -$0.81 falling short of the estimated -$0.04 by -1.92K%, while revenue for the quarter reached $31.44K , missing expectations by -88.05%.
Earnings released on 10 May 2021
EPS came in at -$0.46 , while revenue for the quarter reached $263.15K .
Earnings released on 16 Mar 2021
EPS came in at -$0.24 falling short of the estimated -$0.10 by -140.00%, while revenue for the quarter reached $62.19K .
Earnings released on 17 Nov 2020
EPS came in at -$0.90 , while revenue for the quarter reached $115.55K .
ABVC Stock Performance
Access detailed ABVC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.